| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 11 Feb 2025 | 22 Jan 2025 |
| MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve unaudited financial results, standalone and consolidated, for the quarter and nine months ended December 31, 2024. Kindly find enclosed outcome of Board meeting for the quarter ended and nine months ended December 31, 2024 (As Per BSE Announcement Dated on 11.02.2025) | ||
| Board Meeting | 12 Nov 2024 | 23 Oct 2024 |
| MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve the Unaudited Financial Results (Standalone And Consolidated) For The Quarter and half year ended September 30 2024 PFA (As Per BSE Announcement Dated on 12.11.2024) | ||
| Board Meeting | 13 Aug 2024 | 31 Jul 2024 |
| MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve the unaudited financial results (Standalone and Consolidated) for quarter ended June 30 2024 Kindly find enclosed the outcome of Board meeting. (As Per Bse Announcement Dated on 13.08.2024) | ||
| Board Meeting | 30 May 2024 | 13 May 2024 |
| MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and year ended March 31 2024 and; Recommendation of dividend for FY2023-24 The Board has approved final dividend of Rs. 0.60 per equity share (As Per BSE Announcement dated on 30.05.2024) | ||
Relonchem Ltd has secured Marketing Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets
The US Food and Drug Administration (FDA) approved the pharmaceutical company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
